Karachi: AGP Ltd is poised for substantial growth, supported by strategic acquisitions and a favorable regulatory environment, The report reinstates coverage on AGP with a target price of Rs220 per share, suggesting a 48% increase from current levels.

According to JS Global, AGP is expected to achieve a 16% compound annual growth rate in revenue over the next five years, driven by its robust product portfolio, expanding distribution network, and strategic acquisitions, including those of Sandoz and Viatris. The company aims to maintain an average gross margin of 59% over the same period, benefiting from cost optimization efforts.

The report highlights regulatory changes as a significant factor in AGP's growth strategy, with approximately 55% of its product portfolio no longer subject to pricing regulations due to the deregulation of non-essential drugs. Additionally, a pipeline of innovative products, particularly in the nutraceuticals segment, is expected to contribute further to AGP's revenue growth.

AGP's business model is described as resilient, bolstered by a strong financial position and strategic partnerships, which mitigate risks and ensure long-term sustainability. Despite these strengths, the analysis notes potential challenges, such as the reliance on imported active pharmaceutical ingredients and the impact of currency devaluation, as well as inflationary pressures on essential drug pricing.

JS Global's assessment suggests that AGP's current valuation does not fully reflect its growth potential and profitability, underscoring the company's strong prospects and justifying higher valuation multiples.